Boncur

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Boncur

What is Boncur? (Overview)

Property Description
Active Ingredient Zoledronic acid
Form Solution concentrate for infusion
Pharmacological Class Bisphosphonate
Primary Action Bone metabolism regulator
Origin Synthetic (chemically manufactured)

What Type of Medicine is Boncur?

Boncur is a prescription medication whose active substance is Zoledronic acid, a high-potency agent classified within the bisphosphonate family of drugs. This ingredient is a synthetic compound, chemically manufactured rather than naturally derived, and is characterized by its effects on bone tissue.

Unlike most common oral medicines, Boncur is formulated as a solution concentrate for infusion. This is a significant factor in its use, as it must be administered directly into a vein by a healthcare professional. Its high potency contributes to a long-acting profile, a specialized feature that often allows for less frequent administration than oral alternatives.

Boncur’s General Therapeutic Purpose

The fundamental purpose of Boncur is to act as a potent bone metabolism regulator with a highly effective antiresorptive action. This means the medicine is specifically designed to help control and slow down the rate at which old bone tissue is broken down and removed from the body, helping to shift the bone remodeling balance toward preservation.

By helping to manage the rate of bone loss, the therapy plays a supportive role in maintaining the structural integrity of the skeletal system and stabilizing mineral balance. Zoledronic acid is a potent antiresorptive agent for skeletal health, providing intensive therapy for chronic conditions affecting bone stability.

Regulatory References

  1. NIH/StatPearls

What side effects are possible with Boncur?

Possible Side Effects and Safety Information

The safety profile of zoledronic acid (Boncur’s active ingredient) is classified by regulatory authorities according to the frequency and system-organ class of documented adverse reactions. These classifications reflect how government regulatory documents organize and communicate the medicine’s safety profile.

Frequency-Classified Adverse Reactions

Classification Examples of Effects
Very Common (≥ 1/10) Pyrexia (fever), Myalgia (muscle pain), Arthralgia, Hypophosphatemia
Common (≥ 1/100 to < 1/10) Headache, Nausea, Vomiting, Renal impairment, Flu-like syndrome
Uncommon/Rare Osteonecrosis of the Jaw (ONJ), Atypical femoral fractures, Acute renal failure

The most frequent reactions are generally the Very Common acute phase symptoms, such as fever and muscle pain, which are typically transient and more likely to occur within the first three days following administration. In contrast, severe bone complications, like atypical femoral fractures, are rare and primarily associated with long-term use of bisphosphonates.

Safety Restrictions and Special Populations

Official labeling imposes explicit restrictions regarding the use of zoledronic acid. The medicine is contraindicated in patients with established hypocalcemia and in those with severely impaired renal function (creatinine clearance < 35 mL/min). Caution is advised when used alongside other medications that may affect kidney function (nephrotoxic drugs). Furthermore, the drug is contraindicated for use in pregnant and nursing women, and special care is indicated for monitoring renal function in geriatric patients.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Boncur (Zoledronic acid) is defined by two primary, life-threatening outcomes arising from excessive exposure: severe metabolic disturbances and acute renal toxicity.


Documented Overdose Manifestations

Overdose may present as an exaggeration of the drug's intended action, resulting in severe hypocalcemia (low serum calcium), hypophosphatemia, and hypomagnesemia. The hypocalcemia can be clinically significant, requiring urgent medical intervention. The primary physiological systems affected are the metabolic/electrolyte system and renal function.


Severe Outcomes and Emergency Action

Excessive dosing is documented to cause a rapid deterioration in renal function, with a risk of progression to acute renal failure. This serious outcome necessitates mandatory monitoring of serum creatinine and electrolytes. Patients with pre-existing renal impairment are noted to have an increased risk of severe renal toxicity following high-dose exposure.

If an overdose is suspected or if severe symptoms manifest, immediate medical attention is required. The official regulatory guidance states that management involves symptomatic and supportive treatment. Specifically, clinically significant hypocalcemia must be corrected through intravenous calcium administration. The official labeling confirms that no specific antidote is known for Zoledronic acid overdose.

Therapeutic Uses of Boncur

What Boncur Treats: Main Uses and Benefits

The core therapeutic purpose of Boncur is applied in addressing osteoporosis, a condition where functional stability becomes affected due to progressive bone loss. The medication is applied in addressing the therapeutic domains of postmenopausal osteoporosis.

The medicine is commonly used across conditions presenting with acute episodes of bone weakness. This is relevant in contexts involving heightened systemic burden linked to organ-specific functional stress, such as the skeletal system.

The use of this medication may assist with maintaining functional stability, which helps ease the overall symptom burden associated with physical discomfort. It supports general well-being during symptomatic phases by providing supportive relief when symptoms interfere with routine activities. This ultimately contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relevant for Easing Physical Discomfort

Eligibility and Restrictions for Use

The eligibility for using Boncur (Zoledronic acid) is determined by official regulatory documents based on organ function, age, and pre-existing conditions. Use is permitted for adults (age 18 and older) for the approved indications.

Who Cannot Use Boncur (Contraindications)

Boncur is strictly contraindicated and must not be used in the following populations:

  • Patients with Hypocalcemia (low serum calcium levels), which must be corrected prior to therapy.
  • Individuals with a known hypersensitivity to zoledronic acid or any other bisphosphonate.
  • Patients with severe renal impairment, defined as a Creatinine Clearance (CrCl) less than 35 mL/min or evidence of acute renal impairment.
  • Pregnant and breastfeeding women due to documented risks.

Age and Condition Restrictions

Population Group Regulatory Status
Pediatric Patients (Under 18) Not indicated; safety and efficacy are not established.
Older Adults (Geriatric) Use is permitted, but requires special care to monitor renal function.
Concurrent Therapy Must not be given to patients receiving another zoledronic acid product (e.g., Zometa).
Mineral Imbalances Other pre-existing disturbances of mineral metabolism must be effectively treated before initiation.

Eligibility criteria are rigidly defined by these constraints, limiting use to individuals who meet the minimum renal function standard and lack these specific contraindicated conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Boncur (Zoledronic acid) based on government regulatory labeling.

Documented Interaction Patterns

Interaction Type Interacting Substance/Class Official Regulatory Statement
Prohibited Combination Other Zoledronic Acid Products / Bisphosphonates Co-administration with other zoledronic acid products or other bisphosphonates is officially advised against.
Pharmacodynamic Effect Aminoglycosides & Loop Diuretics These agents may have an additive effect to lower serum calcium or increase the risk of hypocalcemia.
Administration Restriction Calcium/Divalent Cation Solutions The solution must not be mixed with any infusion solutions containing calcium or other divalent cations.
Additive Toxicity Risk Potentially Nephrotoxic Drugs Caution is indicated due to an increased risk of renal toxicity and acute renal impairment.
Exposure Constraint Drugs Primarily Cleared by Kidney Exposure of Boncur may be increased in the presence of impaired renal function, requiring monitoring.

Regulatory Summary

Boncur is not metabolized by the CYP450 enzyme system, meaning interactions driven by this metabolic pathway are not expected. The interaction profile is primarily defined by additive effects on mineral balance and additive toxicity risk to the kidneys. The drug's clearance is directly dependent on renal function, and this relationship is officially acknowledged as an exposure constraint for patients with pre-existing renal impairment.

Mechanism of Action

Targeting the Bone Resorption Mechanism

Boncur's active ingredient, Zoledronic acid, exhibits a high affinity for hydroxyapatite, which concentrates the molecule at sites of active bone turnover. Once released and internalized by the bone-resorbing cells, the osteoclasts, the molecule inhibits the osteoclasts, which affects the process of bone turnover. This binding localizes the drug's effect to the active bone surface.

Disruption of Intracellular Metabolic Pathways

Within the osteoclast, Zoledronic acid acts as an inhibitor of the enzyme Farnesyl Diphosphate Synthase (FPPS), a key enzyme in the mevalonate pathway. This molecular blockade prevents the cell from synthesizing essential signaling lipids, which are required for maintaining the cell's structure and function. The resulting downstream cascade affects the cell's ability to adhere to the bone surface and execute its resorptive function.

Induction of Osteoclast Cell Death

The disruption of the osteoclast's internal structure and signaling mechanisms directly triggers apoptosis (programmed cell death). This targeted inactivation and subsequent elimination of the bone-resorbing cell population results in a significant and prolonged antiresorptive effect. The final physiological consequence is a net decrease in bone resorption, which affects the bone mineral balance.

Dosage and Administration Information

How Boncur is Used: Administration Guidelines

Boncur (Zoledronic acid) is administered exclusively as an Intravenous infusion (IV) under the supervision of a healthcare professional. Its use follows specific protocols to match the therapeutic context.

Administration Context Description
Dose Regimens The dose is determined by the specific condition. A 4 mg single dose is used for malignancy-related bone conditions, while a 5 mg single dose is used for the treatment of osteoporosis or Paget's disease of bone.
Frequency Pattern Schedules vary from once a year (for osteoporosis) to every 3 to 4 weeks (for malignancy-related conditions). In some contexts, the dose may be repeated after a minimum of seven days.
Infusion Protocol The medicine is infused slowly, over a period of no less than 15 minutes, regardless of the dose administered.
Preparation Rules The solution is administered via a separate intravenous line and is not mixed with any solutions containing calcium or other divalent cations.
Renal Adjustment Dose reduction is required for the 4 mg regimen in patients with reduced kidney function (Creatinine Clearance, CrCl, less than or equal to 60 mL/min). The 5 mg regimen is typically restricted for use in patients with CrCl < 35 mL/min.

The need for continued therapy, particularly the annual 5 mg dose for osteoporosis, is re-evaluated periodically by the clinician, generally after five or more years of use. The protocol for the 5 mg dose includes oral Calcium and Vitamin D supplementation to support bone mineral balance. This framework, including the 15-minute minimum infusion time and the strict incompatibility rules, standardizes how the medication is delivered in clinical settings.

Recent Clinical Evidence

Boncur: Recent Clinical Evidence

Research Supporting Use in Postmenopausal Osteoporosis

Research exploring the role of Boncur in postmenopausal osteoporosis often involved large-scale Randomized Controlled Trials (RCTs), typically comparing the medicine against an inactive substance (placebo). These studies focused on monitoring skeletal outcomes, specifically the incidence of new fractures and tracking the numerical measurements of bone mineral density (BMD) changes at the hip and spine over several years. Findings from these core studies report patterns observed in skeletal outcomes and contribute to the broader evidence landscape. However, long-term effects are not fully established beyond the initial trial period for all patients, and results apply only to the populations studied.

Evidence for Specific Populations and Complications

Clinical studies have also explored the role of the medicine for treating osteoporosis in adult men and for managing bone loss associated with long-term glucocorticoid (steroid) use. This research primarily involved short-term studies focusing on measuring BMD outcomes. For these specific groups, the sample sizes were modest, and follow-up durations were limited, meaning long-term fracture data remains insufficient.

Separately, large comparative oncology trials addressed the use of the medicine in research concerning bone complications (Skeletal-Related Events or SREs) associated with advanced cancers. These trials examined the interval to the first Skeletal-Related Event (SRE). Studies described patterns observed in the measured interval to the first SRE compared to control groups across various tumor types.

Evidence Gaps and Areas of Ongoing Review

While the evidence base is extensive, certain areas remain a focus of scientific review. Data for certain groups remain insufficient, especially for patients with other significant underlying health conditions (comorbidities). Comparative evidence against newer bone-modifying treatments is still emerging. Research is ongoing to determine the optimal length of time the medicine should be studied to provide the most characterized outcomes for skeletal health, and the durability of effects after treatment cessation is an area where research is ongoing.

Key Studies & References

  1. Zoledronic acid prevents skeletal complications and is superior to pamidronate in patients with breast cancer with bone metastases: a phase III trial

Frequently Asked Questions (FAQ)

Common questions about Boncur (FAQ)


Q: How quickly does Boncur usually start to show an effect?

Official documentation suggests that for the full desired effect on bone conditions to be clinically assessed, a duration of two to three months of treatment may be necessary. However, an acute phase reaction, often presenting as flu-like symptoms, is frequently reported and can occur within the first three days following the infusion.


Q: How is Boncur different from other treatments prescribed for the same condition?

Boncur's active ingredient, Zoledronic acid, is classified as a bisphosphonate. Official warnings state that patients already receiving another product containing the same active ingredient, such as Zometa or Reclast, should not receive Boncur.


Q: Is Boncur considered a long-term or short-term treatment?

The official treatment duration is determined by the specific medical condition being addressed. For osteoporosis, it is often administered annually, while for certain malignancy-related bone conditions, the regimen requires more frequent, periodic infusions.


Q: Is it common to feel fatigued or tired after taking Boncur?

Regulatory documents state that fatigue or tiredness is a very common adverse reaction. This symptom is often part of an acute-phase reaction that can occur within the first three days following the intravenous administration.


Q: Can Boncur cause changes in appetite or body weight?

Loss of appetite (anorexia) is listed as a common adverse effect in official documents. Weight increase has also been reported by patients in post-marketing experience.


Q: Does Boncur interact with common pain relievers like ibuprofen or acetaminophen?

Regulatory information indicates that Boncur may interact with nonsteroidal anti-inflammatory drugs (NSAIDs), a class that includes common pain relievers like ibuprofen. This medication requires caution when used with certain pain relievers.


Q: Are there any specific foods or drinks that should be avoided while taking Boncur?

Official documents do not list any specific foods or drinks that a patient must avoid. However, the intravenous solution itself must never be mixed with solutions that contain calcium or other divalent cations.


Q: Can Boncur be used safely by patients with underlying heart conditions?

Official documentation advises that use of this medication may require special caution in patients with pre-existing heart disease. Potential cardiac side effects, such as changes in heart rhythm (atrial fibrillation) and blood pressure fluctuations, have been reported in clinical experience.


Q: What is the risk of developing a serious allergic reaction to Boncur?

Severe allergic reactions (hypersensitivity) are a reported possibility. The medication is not to be used if a patient has a known allergy to zoledronic acid or any other bisphosphonate drug.


Q: Can taking Boncur affect the results of other medical tests?

The medication is noted in official documentation to alter serum levels of minerals, including calcium, phosphate, and potassium. These changes are routinely monitored through laboratory tests during treatment.


Q: What kind of monitoring or follow-up is required while on Boncur?

Official prescribing information states that specific monitoring is required, including checking kidney function (serum creatinine) and serum calcium levels before each dose. Patients are often officially required to receive calcium and Vitamin D supplements.


Q: What are the most common reasons people stop taking Boncur?

Regulatory warnings indicate that the onset of severe, incapacitating bone, joint, or muscle pain is one of the adverse effects that may lead a healthcare provider to withhold future doses of the medication.


Q: What does the research evidence say about Boncur's long-term safety?

Official prescribing information notes that long-term use is associated with rare but serious complications. These include osteonecrosis of the jaw (ONJ) and atypical femoral fractures, which are unusual breaks in the thigh bone.


Q: Are there any reported interactions between Boncur and herbal supplements?

While specific adverse interactions with herbal supplements are not documented, regulatory information advises that due to the potential for interactions, all herbal products and supplements should be noted when discussing treatment.


Q: How is Boncur processed and eliminated by the body?

The active ingredient concentrates by binding directly to the bone tissue. It is notable that the medication is not metabolized by the liver’s enzyme systems; instead, it is primarily cleared from the body by the kidneys.


Q: Can Boncur be taken with coffee or other caffeinated beverages?

Official regulatory information does not list a specific interaction with coffee or caffeine. Patients are generally advised to eat normally on the day they receive their treatment.


Q: Is Boncur available as a generic medicine?

The active ingredient, Zoledronic acid, is available from various generic manufacturers. Boncur is one of the brand names for this active substance, alongside Reclast and Zometa.


Q: Can Boncur be used by people who have liver or kidney problems?

The medication is not intended for use in patients with severe kidney impairment. For severe liver impairment, safety and effectiveness have not been established according to official documentation.


Q: What is the typical timeframe for a patient to be on Boncur?

The timeframe is highly variable and determined by the specific indication. For osteoporosis treatment, official guidance indicates the need for continued annual therapy is subject to re-evaluation by a clinician after five or more years of use.


Q: How does Boncur affect daily activities like driving or operating machinery?

Caution is officially advised regarding daily activities like driving or operating machinery. The possibility of dizziness means that caution should be exercised regarding driving or operating machinery. If dizziness occurs, these activities may need to be avoided until the symptom resolves.


Q: How does Boncur interact with alcohol, and is it completely forbidden?

The official documents do not list a direct drug-to-alcohol interaction. While a direct drug-to-alcohol interaction is not listed, heavy alcohol consumption is noted to contribute to bone loss, which could undermine the treatment’s therapeutic goal.


Q: What should a person do if they forget to take a dose of Boncur?

Since Boncur is an intravenous infusion that must be given by a healthcare professional, the patient is not responsible for the timing. If a scheduled intravenous infusion is missed, the patient is generally advised to contact their healthcare provider to arrange a new appointment.


Q: Can Boncur interact with hormonal birth control medications?

Regulatory documents do not list a specific interaction with hormonal birth control. Due to the potential for fetal harm, regulatory information states that women who are able to become pregnant are advised to use effective contraception during treatment and for a specified period thereafter.


Q: What are the official guidelines regarding stopping Boncur treatment?

Continuation of the annual dose for osteoporosis is subject to periodic re-evaluation by a clinician. Official guidelines also state that if a patient develops severe, incapacitating bone, joint, or muscle pain, future doses should be withheld.


Q: Why does Boncur require a prescription from a doctor?

This medication requires a prescription because it must be administered by a healthcare professional as an intravenous infusion. It also necessitates specific clinical monitoring, such as checking kidney function and calcium levels, due to the risk of serious adverse effects.


Q: Can Boncur cause changes in mood or emotional stability?

Official safety information indicates that psychiatric adverse effects have been reported with this medication. These reported effects include anxiety, depression, insomnia (difficulty sleeping), and agitation.


Q: How long after stopping Boncur do the effects wear off?

Due to the way the active ingredient binds and concentrates in the bone tissue, its effects can persist for a long time after the infusion has ended. The full duration of these effects following treatment cessation is a subject noted in clinical understanding.


Q: Does Boncur have a Black Box Warning, and what does it mean?

The prescribing information contains important warnings regarding the risk of serious side effects. These risks include severe kidney problems (renal failure), osteonecrosis of the jaw (ONJ), and unusual fractures of the thigh bone, all of which require specific patient monitoring.


Q: Is there a maximum length of time a person can safely take Boncur?

Official guidelines do not establish a set maximum duration for all patients. However, for osteoporosis treatment, the need for continued annual therapy must be re-evaluated by a clinician, typically after five or more years of use.


Q: What should I know about taking Boncur if I have a history of seizures?

Seizures are a reported severe, though less common, adverse effect of the medication. It is noted that the medication is not to be used in patients with low serum calcium levels (hypocalcemia), a condition that may contribute to seizures.

How should Boncur be stored and disposed of?

Official Storage Requirements

Regulatory documents stipulate specific conditions for storing Zoledronic acid infusion solution. The unopened product must be stored at Controlled Room Temperature, typically 25 mathrmC (77 mathrmF), with excursions permitted up to 30 mathrmC. It is an explicit requirement that the solution concentrate must not be frozen.

Once diluted, the prepared solution has a labeled stability limit of 24 hours when kept under refrigeration at 2 mathrmC to 8 mathrmC. The vial is designated for single-use only.

Handling and Disposal

To ensure safety, the medication must always be stored out of the sight and reach of children. A critical handling constraint is that the solution must not be mixed or allowed to contact any fluid containing calcium or other divalent cations.

Disposal instructions state that unused medicinal product or waste material must be discarded in accordance with local requirements. The medicine should not be disposed of via wastewater or typical household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Boncur found in:

A-Z Index: